- Home
- TIXT vs ORKA Comparison
TIXT vs ORKA Comparison
Compare TIXT & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIXT
- ORKA
- Stock Information
- Founded
- TIXT 2005
- ORKA 2004
- Country
- TIXT Canada
- ORKA United States
- Employees
- TIXT N/A
- ORKA N/A
- Industry
- TIXT EDP Services
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TIXT Technology
- ORKA Health Care
- Exchange
- TIXT Nasdaq
- ORKA Nasdaq
- Market Cap
- TIXT 812.7M
- ORKA 354.2M
- IPO Year
- TIXT 2021
- ORKA N/A
- Fundamental
- Price
- TIXT $3.76
- ORKA $14.21
- Analyst Decision
- TIXT Hold
- ORKA Strong Buy
- Analyst Count
- TIXT 9
- ORKA 8
- Target Price
- TIXT $4.17
- ORKA $39.71
- AVG Volume (30 Days)
- TIXT 1.3M
- ORKA 364.0K
- Earning Date
- TIXT 08-01-2025
- ORKA 08-15-2025
- Dividend Yield
- TIXT N/A
- ORKA N/A
- EPS Growth
- TIXT N/A
- ORKA N/A
- EPS
- TIXT N/A
- ORKA N/A
- Revenue
- TIXT $2,671,000,000.00
- ORKA N/A
- Revenue This Year
- TIXT $3.61
- ORKA N/A
- Revenue Next Year
- TIXT $3.59
- ORKA N/A
- P/E Ratio
- TIXT N/A
- ORKA N/A
- Revenue Growth
- TIXT N/A
- ORKA N/A
- 52 Week Low
- TIXT $2.13
- ORKA $5.49
- 52 Week High
- TIXT $6.86
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- TIXT 66.56
- ORKA N/A
- Support Level
- TIXT $3.55
- ORKA N/A
- Resistance Level
- TIXT $3.92
- ORKA N/A
- Average True Range (ATR)
- TIXT 0.10
- ORKA 0.00
- MACD
- TIXT -0.01
- ORKA 0.00
- Stochastic Oscillator
- TIXT 60.71
- ORKA 0.00
About TIXT TELUS International (Cda) Inc. Subordinate Voting Shares
TELUS International (Cda) Inc is a digital customer experience innovator that designs, builds, and delivers next-generation solutions. Its clients include companies across several verticals, including Tech and Games, eCommerce and FinTech, Banking, Financial Services and Insurance, Communications and Media, and Healthcare. The solutions offered by the company include Digital Experience, Customer Experience, Advisory Services, and Back Office and Automation among other services. Geographically, it derives a majority of its revenue from the European region.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.